[REVISION HISTORY]

Insmed financial performance and revenue growth

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-08 19:31 UTC → 2026-08-23 10:10 UTC · added ~~removed~~

Insmed Inc. has demonstrated strong financial performance driven by its biotechnology products. Following ~~analyst upgrades and~~ positive reception to earnings, the company reported significant second-quarter revenue growth, totaling $425.5 ~~million.~~ million, compared to $107.4 million in the previous year. A primary driver for this growth was the bronchiectasis treatment BRINSUPRI, which saw a 49% sequential revenue ~~increase.~~ increase to $309.2 million. Consequently, Insmed raised its full-year 2026 revenue guidance for BRINSUPRI to a range of $1.25 billion to $1.4 billion and increased its long-term peak sales ~~estimates~~ estimate for the drug to over $7 billion. The company estimates its three lead ~~programs.~~ programs, including TPIP and ARIKAYCE, could generate more than $14 billion in combined peak revenue. The company ~~also~~ reported a narrowing quarterly net loss of $13.2 million, down from $321.7 million a year earlier, and ended June with approximately $1.2 billion in cash and marketable securities. Institutional interest has surged, with Duquesne Capital Management making Insmed one of its top five positions. Other asset managers, including Assenagon Asset Management, have also significantly expanded their holdings. Operationally, Insmed is advancing clinical studies, such as the ‘BEST-BE’ observational study, while preparing for potential international ~~expansion, including~~ expansion and pending regulatory decisions in ~~Japan.~~ Japan expected in the second half of 2026.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.